Related Experiment Video
Updated: Jun 22, 2026

Evaluation of Caspase Activation to Assess Innate Immune Cell Death
Published on: January 20, 2023
KLF4 suppresses HDACi induced caspase activation and the SAPK pathway by targeting p57(Kip2)
Nung Ky1, Chuan Bian Lim, Jinming Li
1Nanyang Technological University, Singapore, Singapore.
Abstract:
Kruppel-like factor 4 (KLF4) belongs to a family of evolutionarily conserved zinc finger-containing transcription factors. It has been shown to mediate self renewal and pluripotency, regulate adipogenesis and play a critical role in monocyte differentiation. KLF4 is also highly expressed in squamous cell carcinomas and in 70% of all primary human breast cancers, suggesting a putative role for KLF4 as being an oncogene and as an antiapoptotic factor. However, the mechanism of this regulation remains unclear. Here, we show that KLF4 is induced during histone deacetylase inhibitor treatment, and regulates the extrinsic apoptosis pathway by inhibiting caspase cleavage. In addition, KLF4 binds to the p57(Kip2) promoter and transcriptionally upregulates its expression, which in turn inhibits the stress activated protein kinase cascade and c-Jun phosphorylation. Our findings indicate that in cancer cells that express high levels of KLF4 may be refractory to HDACi treatment. Results of our study demonstrate an unexpected antiapoptotic function of KLF4, and suggest an important cell fate determinant following histone deacetylase inhibitor induced apoptosis.
Insights
Kruppel-like factor 4 (KLF4) unexpectedly inhibits apoptosis by blocking caspase cleavage and upregulating p57(Kip2). High KLF4 levels may cause cancer cells to resist HDAC inhibitor treatments.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Biology
Background:
- Kruppel-like factor 4 (KLF4) is a transcription factor involved in cell differentiation and pluripotency.
- KLF4 is highly expressed in various cancers, suggesting oncogenic and antiapoptotic roles.
- The precise mechanisms of KLF4's function in cancer and apoptosis remain unclear.
Purpose of the Study:
- To elucidate the role of KLF4 in apoptosis regulation, particularly during histone deacetylase inhibitor (HDACi) treatment.
- To investigate KLF4's interaction with apoptotic pathways and its impact on cancer cell response to HDACi.
Main Methods:
- Analysis of KLF4 induction during HDACi treatment.
- Investigation of KLF4's effect on the extrinsic apoptosis pathway, including caspase cleavage.
- Chromatin immunoprecipitation and reporter assays to assess KLF4 binding to the p57(Kip2) promoter.
- Examination of KLF4's influence on the stress-activated protein kinase cascade and c-Jun phosphorylation.
Main Results:
- KLF4 is induced by HDACi treatment and inhibits apoptosis by preventing caspase cleavage.
- KLF4 directly binds to the p57(Kip2) promoter, leading to its transcriptional upregulation.
- Upregulation of p57(Kip2) by KLF4 suppresses the stress-activated protein kinase cascade and c-Jun phosphorylation.
- Cancer cells with high KLF4 expression may exhibit resistance to HDACi therapy.
Conclusions:
- KLF4 possesses an unexpected antiapoptotic function in cancer cells.
- KLF4 acts as a critical determinant of cell fate in response to HDACi-induced apoptosis.
- These findings highlight KLF4's complex role in cancer and suggest therapeutic implications for HDACi treatment resistance.
Related Concept Videos
Caspases
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway
The JAK-STAT Signaling Pathway
MAPK Signaling Cascades
Anaphase Promoting Complex

